![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NR2C1 |
Gene summary for NR2C1 |
![]() |
Gene information | Species | Human | Gene symbol | NR2C1 | Gene ID | 7181 |
Gene name | nuclear receptor subfamily 2 group C member 1 | |
Gene Alias | TR2 | |
Cytomap | 12q22 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | H9NIM3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7181 | NR2C1 | NAFLD1 | Human | Liver | NAFLD | 1.53e-03 | 5.13e-01 | -0.04 |
7181 | NR2C1 | S43 | Human | Liver | Cirrhotic | 1.05e-02 | -1.07e-01 | -0.0187 |
7181 | NR2C1 | HCC1_Meng | Human | Liver | HCC | 1.14e-38 | -2.44e-02 | 0.0246 |
7181 | NR2C1 | HCC2_Meng | Human | Liver | HCC | 1.97e-11 | 5.43e-02 | 0.0107 |
7181 | NR2C1 | HCC1 | Human | Liver | HCC | 5.64e-06 | 2.74e+00 | 0.5336 |
7181 | NR2C1 | HCC2 | Human | Liver | HCC | 1.00e-05 | 2.36e+00 | 0.5341 |
7181 | NR2C1 | S014 | Human | Liver | HCC | 8.86e-03 | 2.84e-01 | 0.2254 |
7181 | NR2C1 | S015 | Human | Liver | HCC | 2.44e-07 | 4.81e-01 | 0.2375 |
7181 | NR2C1 | S016 | Human | Liver | HCC | 2.83e-03 | 3.25e-01 | 0.2243 |
7181 | NR2C1 | S027 | Human | Liver | HCC | 3.71e-03 | 4.04e-01 | 0.2446 |
7181 | NR2C1 | S029 | Human | Liver | HCC | 3.03e-02 | 2.89e-01 | 0.2581 |
7181 | NR2C1 | C04 | Human | Oral cavity | OSCC | 4.13e-16 | 5.96e-01 | 0.2633 |
7181 | NR2C1 | C21 | Human | Oral cavity | OSCC | 3.43e-21 | 5.20e-01 | 0.2678 |
7181 | NR2C1 | C30 | Human | Oral cavity | OSCC | 1.20e-19 | 5.70e-01 | 0.3055 |
7181 | NR2C1 | C43 | Human | Oral cavity | OSCC | 4.83e-02 | 1.01e-01 | 0.1704 |
7181 | NR2C1 | C46 | Human | Oral cavity | OSCC | 3.83e-11 | 2.31e-01 | 0.1673 |
7181 | NR2C1 | C08 | Human | Oral cavity | OSCC | 4.40e-09 | 1.98e-01 | 0.1919 |
7181 | NR2C1 | C09 | Human | Oral cavity | OSCC | 4.36e-06 | 1.15e-01 | 0.1431 |
7181 | NR2C1 | LN22 | Human | Oral cavity | OSCC | 8.93e-08 | 6.83e-01 | 0.1733 |
7181 | NR2C1 | LN46 | Human | Oral cavity | OSCC | 5.95e-06 | 1.66e-01 | 0.1666 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0030522110 | Esophagus | ESCC | intracellular receptor signaling pathway | 170/8552 | 265/18723 | 8.58e-10 | 2.09e-08 | 170 |
GO:0048545111 | Esophagus | ESCC | response to steroid hormone | 204/8552 | 339/18723 | 4.47e-08 | 8.11e-07 | 204 |
GO:0071383110 | Esophagus | ESCC | cellular response to steroid hormone stimulus | 127/8552 | 204/18723 | 1.26e-06 | 1.55e-05 | 127 |
GO:004340119 | Esophagus | ESCC | steroid hormone mediated signaling pathway | 87/8552 | 136/18723 | 1.25e-05 | 1.15e-04 | 87 |
GO:000975516 | Esophagus | ESCC | hormone-mediated signaling pathway | 106/8552 | 190/18723 | 3.13e-03 | 1.30e-02 | 106 |
GO:004838412 | Esophagus | ESCC | retinoic acid receptor signaling pathway | 22/8552 | 31/18723 | 3.90e-03 | 1.58e-02 | 22 |
GO:00485457 | Liver | NAFLD | response to steroid hormone | 75/1882 | 339/18723 | 3.44e-11 | 1.12e-08 | 75 |
GO:00713836 | Liver | NAFLD | cellular response to steroid hormone stimulus | 48/1882 | 204/18723 | 1.50e-08 | 1.83e-06 | 48 |
GO:00305226 | Liver | NAFLD | intracellular receptor signaling pathway | 55/1882 | 265/18723 | 1.39e-07 | 1.03e-05 | 55 |
GO:00097556 | Liver | NAFLD | hormone-mediated signaling pathway | 39/1882 | 190/18723 | 1.15e-05 | 3.58e-04 | 39 |
GO:00434016 | Liver | NAFLD | steroid hormone mediated signaling pathway | 28/1882 | 136/18723 | 1.78e-04 | 3.14e-03 | 28 |
GO:004854512 | Liver | Cirrhotic | response to steroid hormone | 146/4634 | 339/18723 | 7.87e-14 | 6.76e-12 | 146 |
GO:007138312 | Liver | Cirrhotic | cellular response to steroid hormone stimulus | 90/4634 | 204/18723 | 1.04e-09 | 4.70e-08 | 90 |
GO:003052212 | Liver | Cirrhotic | intracellular receptor signaling pathway | 105/4634 | 265/18723 | 5.44e-08 | 1.69e-06 | 105 |
GO:004340111 | Liver | Cirrhotic | steroid hormone mediated signaling pathway | 58/4634 | 136/18723 | 3.44e-06 | 5.95e-05 | 58 |
GO:000975511 | Liver | Cirrhotic | hormone-mediated signaling pathway | 71/4634 | 190/18723 | 7.09e-05 | 7.98e-04 | 71 |
GO:0048385 | Liver | Cirrhotic | regulation of retinoic acid receptor signaling pathway | 9/4634 | 16/18723 | 6.94e-03 | 3.38e-02 | 9 |
GO:0048384 | Liver | Cirrhotic | retinoic acid receptor signaling pathway | 14/4634 | 31/18723 | 1.05e-02 | 4.65e-02 | 14 |
GO:003052222 | Liver | HCC | intracellular receptor signaling pathway | 171/7958 | 265/18723 | 3.00e-13 | 1.61e-11 | 171 |
GO:004854522 | Liver | HCC | response to steroid hormone | 206/7958 | 339/18723 | 6.81e-12 | 2.92e-10 | 206 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NR2C1 | SNV | Missense_Mutation | c.265N>G | p.Leu89Val | p.L89V | P13056 | protein_coding | tolerated_low_confidence(0.06) | benign(0.007) | TCGA-AN-A0AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
NR2C1 | SNV | Missense_Mutation | c.883N>C | p.Met295Leu | p.M295L | P13056 | protein_coding | tolerated(1) | benign(0) | TCGA-E9-A22B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
NR2C1 | SNV | Missense_Mutation | novel | c.1210N>A | p.Ser404Thr | p.S404T | P13056 | protein_coding | deleterious(0.03) | probably_damaging(0.99) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
NR2C1 | SNV | Missense_Mutation | c.1156G>A | p.Glu386Lys | p.E386K | P13056 | protein_coding | tolerated(0.12) | benign(0.009) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
NR2C1 | SNV | Missense_Mutation | c.1429N>C | p.Glu477Gln | p.E477Q | P13056 | protein_coding | deleterious(0.01) | benign(0.277) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
NR2C1 | SNV | Missense_Mutation | c.1156G>A | p.Glu386Lys | p.E386K | P13056 | protein_coding | tolerated(0.12) | benign(0.009) | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
NR2C1 | SNV | Missense_Mutation | novel | c.967N>A | p.Ala323Thr | p.A323T | P13056 | protein_coding | deleterious(0.04) | probably_damaging(0.989) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
NR2C1 | SNV | Missense_Mutation | novel | c.1366A>G | p.Asn456Asp | p.N456D | P13056 | protein_coding | deleterious(0.02) | probably_damaging(0.98) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
NR2C1 | SNV | Missense_Mutation | c.1687A>G | p.Thr563Ala | p.T563A | P13056 | protein_coding | tolerated(0.7) | benign(0.005) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
NR2C1 | SNV | Missense_Mutation | c.432T>A | p.Asn144Lys | p.N144K | P13056 | protein_coding | tolerated(0.17) | probably_damaging(0.996) | TCGA-AZ-6605-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folfox | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7181 | NR2C1 | NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | RETINOIC ACID | 9071982 |
Page: 1 |